EICHOR
● Active Not Recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
About this study
The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (81)
| Beijing Cancer Hospital | Beijing, China | — |
| Beijing Chest Hospital. Capital Medical University | Beijing, China | — |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | — |
| Peking University Third Hospital | Beijing, China | — |
| The First Hospital of Jilin University | Changchun, China | — |
| Jilin Cancer Hospital | Changcun, China | — |
| Hunan Cancer Hospital | Changsha, China | — |
| Xiangya Hospital, Central South University | Changsha, China | — |
| Xiangya Second Hospital of Central South University | Changsha, China | — |
| Chengdu Fifth People's Hospital | Chengdu, China | — |
| Sichuan Provincial People's Hospital | Chengdu, China | — |
| The General Hospital of Western Theater Command | Chengdu, China | — |
+ 69 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06711900